Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-26 pm EST
22.39 USD   -0.93%
01/23SVB Securities Adjusts Price Target on Rocket Pharmaceuticals to $49 From $50, Maintains Outperform Rating
MT
01/09Transcript : Rocket Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 02:15 PM
CI
01/09Rocket Pharmaceuticals Sees 'Positive' Early Trial Data for RP-A501 in Danon Disease
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Rocket Pharmaceuticals : Presents Positive LAD-l Clinical Update and Comprehensive IMO Preclinical Review at the European Society for Immunodeficiencies 2020 Meeting

10/19/2020 | 10:22am EST

NEW YORK - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ('Rocket'), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces clinical data at the European Society for Immunodeficiencies (ESID) 2020 Meeting being held virtually October 14-17, 2020.

An oral presentation provides positive longer-term follow-up data from the Phase 1/2 clinical trial of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I). An e-poster highlights preclinical study data on RP-L401 for Infantile Malignant Osteopetrosis (IMO) supporting clinical development of the trial.

'Today, Rocket presents positive results from our LAD-I gene therapy trial demonstrating further clinical benefit in this severely affected patient population,' said Jonathan Schwartz, M.D. Chief Medical Officer and Senior Vice President of Rocket. 'Patients with LAD-I have markedly diminished expression of the integrin CD18 and suffer from life-threatening bacterial and fungal infections. Natural history studies indicate that an increase in CD18 expression to 4-10% is associated with survival into adulthood. The two patients enrolled in our Phase 1 trial demonstrated restored CD18 expression substantially exceeding this threshold. In addition, we continue to observe a durable treatment effect in the patient followed through one year, with improvement of multiple disease-related skin lesions after therapy and no further requirements for prophylactic anti-infectives.'

Dr. Schwartz continued, 'In addition, preclinical results in Infantile Malignant Osteopetrosis represent an early positive signal of in vivo efficacy that support evaluation of RP-L401 in a Phase 1 trial. IMO is a devastating bone resorption disorder resulting in skeletal deformities, neurologic abnormalities and bone marrow failure. Rocket has developed RP-L401 as a potential treatment option to prevent the devastating morbidity and childhood mortality associated with IMO. Preclinical data indicate that even a modest level of engraftment can correct the disease phenotype, with increased long-term survival, growth, and normalized bone and tooth development.'

About Leukocyte Adhesion Deficiency-I

Severe Leukocyte Adhesion Deficiency-I (LAD-I) is a rare, autosomal recessive pediatric disease caused by mutations in the ITGB2 gene encoding for the beta-2 integrin component CD18. CD18 is a key protein that facilitates leukocyte adhesion and extravasation from blood vessels to combat infections. As a result, children with severe LAD-I are often affected immediately after birth. During infancy, they suffer from recurrent life-threatening bacterial and fungal infections that respond poorly to antibiotics and require frequent hospitalizations. Children who survive infancy experience recurrent severe infections including pneumonia, gingival ulcers, necrotic skin ulcers, and septicemia. Without a successful bone marrow transplant, mortality in patients with severe LAD-I is 60-75% prior to the age of 2 and survival beyond the age of 5 is uncommon. There is a high unmet medical need for patients with severe LAD-I.

Rocket's LAD-I research is made possible by a grant from the California Institute for Regenerative Medicine (Grant Number CLIN2-11480). The contents of this press release are solely the responsibility of Rocket and do not necessarily represent the official views of CIRM or any other agency of the State of California.

About Infantile Malignant Osteopetrosis

Infantile Malignant Osteopetrosis (IMO) is a rare, severe autosomal recessive disorder caused by mutations in the TCIRG1 gene, which is critical for the process of bone resorption. Mutations in TCIRG1 interfere with the function of osteoclasts, cells which are essential for normal bone remodeling and growth, leading to skeletal malformations, including fractures and cranial deformities which cause neurologic abnormalities including vision and hearing loss. Patients often have endocrine abnormalities and progressive, frequently fatal bone marrow failure. As a result, death is common within the first decade of life. IMO has an estimated incidence of 1 in 200,000. The only treatment option currently available for IMO is an allogenic bone marrow transplant (HSCT), which allows for the restoration of bone resorption by donor-derived osteoclasts which originate from hematopoietic cells. Long-term survival rates are lower in IMO than those associated with HSCT for many other non-malignant hematologic disorders; severe HSCT-related complications are frequent. There is an urgent need for additional treatment options.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ('Rocket') is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket's first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.

Rocket Cautionary Statement Regarding Forward-Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon Disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'will give,' 'estimate,' 'seek,' 'will,' 'may,' 'suggest' or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket's ongoing trials, our expectations regarding when clinical trial sites will resume normal business operations, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled 'Risk Factors' in Rocket's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed August 5, 2020 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Claudine Prowse

Email: investors@rocketpharma.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ROCKET PHARMACEUTICALS, INC.
01/23SVB Securities Adjusts Price Target on Rocket Pharmaceuticals to $49 From $50, Maintain..
MT
01/09Transcript : Rocket Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan..
CI
01/09Rocket Pharmaceuticals Sees 'Positive' Early Trial Data for RP-A501 in Danon Disease
MT
01/09Rocket Pharmaceuticals, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/09Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 ..
BU
01/09Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 ..
CI
01/03Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
BU
01/02Certain Restricted Stock Units of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up..
CI
01/02Certain Common Stock of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement..
CI
2022BofA Securities Cuts Price Target on Rocket Pharmaceuticals to $35 From $38, Maintains ..
MT
More news
Analyst Recommendations on ROCKET PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 0,10 M - -
Net income 2022 -215 M - -
Net cash 2022 319 M - -
P/E ratio 2022 -7,13x
Yield 2022 -
Capitalization 1 695 M 1 695 M -
EV / Sales 2022 13 752x
EV / Sales 2023 69,5x
Nbr of Employees 151
Free-Float 95,7%
Chart ROCKET PHARMACEUTICALS, INC.
Duration : Period :
Rocket Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 22,39 $
Average target price 51,77 $
Spread / Average Target 131%
EPS Revisions
Managers and Directors
Gaurav D. Shah Chief Executive Officer & Director
Kinnari Patel President & Chief Operating Officer
John C. Militello Treasurer, Chief Financial & Accounting Officer
Roderick T. Wong Chairman
Jonathan David Schwartz Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ROCKET PHARMACEUTICALS, INC.12.52%1 710
VERTEX PHARMACEUTICALS8.58%80 930
REGENERON PHARMACEUTICALS, INC.0.83%79 159
WUXI APPTEC CO., LTD.20.37%42 279
BIONTECH SE-4.99%34 686
BEIGENE, LTD.19.81%27 392